192 related articles for article (PubMed ID: 18550118)
1. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
Sokoll LJ; Wang Y; Feng Z; Kagan J; Partin AW; Sanda MG; Thompson IM; Chan DW
J Urol; 2008 Aug; 180(2):539-43; discussion 543. PubMed ID: 18550118
[TBL] [Abstract][Full Text] [Related]
2. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.
Le BV; Griffin CR; Loeb S; Carvalhal GF; Kan D; Baumann NA; Catalona WJ
J Urol; 2010 Apr; 183(4):1355-9. PubMed ID: 20171670
[TBL] [Abstract][Full Text] [Related]
3. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
Mikolajczyk SD; Catalona WJ; Evans CL; Linton HJ; Millar LS; Marker KM; Katir D; Amirkhan A; Rittenhouse HG
Clin Chem; 2004 Jun; 50(6):1017-25. PubMed ID: 15054080
[TBL] [Abstract][Full Text] [Related]
4. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.
Sokoll LJ; Chan DW; Mikolajczyk SD; Rittenhouse HG; Evans CL; Linton HJ; Mangold LA; Mohr P; Bartsch G; Klocker H; Horninger W; Partin AW
Urology; 2003 Feb; 61(2):274-6. PubMed ID: 12597929
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
6. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
Sokoll LJ; Sanda MG; Feng Z; Kagan J; Mizrahi IA; Broyles DL; Partin AW; Srivastava S; Thompson IM; Wei JT; Zhang Z; Chan DW
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1193-200. PubMed ID: 20447916
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
[TBL] [Abstract][Full Text] [Related]
8. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
Liang Y; Ankerst DP; Ketchum NS; Ercole B; Shah G; Shaughnessy JD; Leach RJ; Thompson IM
J Urol; 2011 Jan; 185(1):104-10. PubMed ID: 21074193
[TBL] [Abstract][Full Text] [Related]
10. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
11. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
Akduman B; Alkibay T; Tuncel A; Bozkirli I
Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
[TBL] [Abstract][Full Text] [Related]
12. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.
Catalona WJ; Partin AW; Sanda MG; Wei JT; Klee GG; Bangma CH; Slawin KM; Marks LS; Loeb S; Broyles DL; Shin SS; Cruz AB; Chan DW; Sokoll LJ; Roberts WL; van Schaik RH; Mizrahi IA
J Urol; 2011 May; 185(5):1650-5. PubMed ID: 21419439
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
14. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL.
Fujizuka Y; Ito K; Oki R; Suzuki R; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
Int J Urol; 2017 Aug; 24(8):602-609. PubMed ID: 28560739
[TBL] [Abstract][Full Text] [Related]
16. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
[TBL] [Abstract][Full Text] [Related]
17. Individualized prostate-specific antigen threshold values to avoid overdiagnosis of prostate cancer and reduce unnecessary biopsy in elderly men.
Kanao K; Komori O; Nakashima J; Ohigashi T; Kikuchi E; Miyajima A; Nakagawa K; Eguchi S; Oya M
Jpn J Clin Oncol; 2014 Sep; 44(9):852-9. PubMed ID: 25030213
[TBL] [Abstract][Full Text] [Related]
18. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
19. Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels.
Baltaci S; Aksoy H; Türkölmez K; Elhan AH; Ozden E; Göğüş O
Urol Int; 2003; 70(1):36-41. PubMed ID: 12566813
[TBL] [Abstract][Full Text] [Related]
20. Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men.
Rhodes T; Jacobson DJ; McGree ME; St Sauver JL; Sarma AV; Girman CJ; Lieber MM; Klee GG; Demissie K; Jacobsen SJ
J Urol; 2012 Jan; 187(1):92-6. PubMed ID: 22093189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
